Research programme: PLK4 inhibitors - ORIC Pharmaceuticals
Latest Information Update: 20 Apr 2023
At a glance
- Originator ORIC Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action PLK4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Neuroblastoma
Most Recent Events
- 18 Apr 2023 Pharmacodynamics data from a preclinical studies in Prostate Cancer released by ORIC Pharmaceuticals
- 14 Mar 2023 Preclinical trials in Neuroblastoma in USA (PO) as of March 2023
- 14 Mar 2023 Pharmacodynamics data from preclinical studies in Neuroblastoma and Breast cancer released by ORIC Pharmaceuticals